It obtained FDA approval for first-line treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC) in June 2013 and is also in clinical trials for various solid tumors with encouraging prospects [21–23]. Here, EGFR is linked to non-small cell lung carcinoma.